Compass Group PLC Sponsored ADR (CMPGY)
Compass Q2 Earnings Call Highlights
Compass NYSE: COMP reported record second-quarter revenue and adjusted EBITDA, with results exceeding its guidance range as the company continued integrating the Anywhere businesses acquired earlier this year.
Compass, Inc. (COMP) Q2 2026 Earnings Call Transcript
Compass, Inc. (COMP) Q2 2026 Earnings Call Transcript
Compass, Inc. (COMP) Q2 Earnings Match Estimates
Compass, Inc. (COMP) came out with quarterly earnings of $0.11 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.07 per share a year ago.
Compass Pathways: The Psilocybin Biotech Leader With Strong Momentum
CMPS leads regulated psilocybin with two successful Phase 3 trials and a rolling FDA submission, giving COMP360 a valuable head start in treatment-resistant depression. The core case rests on vast unmet need in depression, while encouraging PTSD data and other possible uses provide meaningful long-term upside beyond the first indication. Lilly's move for Atai validates the field and raises the competitive bar, but CMPS retains its clinical lead and cash runway; a 2% pro-forma position keeps risk proportionate.
Compass Group PLC (CMPGY) Q3 2026 Sales/Trading Call Transcript
Compass Group PLC (CMPGY) Q3 2026 Sales/Trading Call Transcript
Compass Group Q3 Earnings Call Highlights
Compass Group LON: CPG reported another strong quarter in its third-quarter trading update, with Group Chief Executive Officer Dominic Blakemore saying the company delivered organic revenue growth of more than 7% and maintained client retention at 96%.
Compass Pathways gains Jefferies support as COMP360 data distinguishes psychological support from psychotherapy
Compass Pathways (NASDAQ:CMPS)'s COMP360 treatment model may face fewer regulatory hurdles as new Phase II analysis distinguishes the company's psychological support approach from psychotherapy, Jefferies analysts have highlighted. In a note reviewing a post-hoc analysis of Compass Pathways (NASDAQ:CMPS)' completed Phase II open-label trial of COMP360 in post-traumatic stress disorder (PTSD), Jefferies wrote that the study provided further detail on how the company's treatment model separates monitoring and support during dosing sessions from traditional talk therapy.
Top FTSE 100 Index shares to watch next week: Airtel, BT Group, Compass Group
The FTSE 100 Index has remained in a narrow range this week as traders reacted to the rising tensions between the US and Iran. It also wavered as the United States earnings season started, with big names like JPMorgan, Goldman Sachs, and Netflix releasing their earnings.
Compass Therapeutics: A 50% Price Cut Hiding A Regulatory Mispricing Opportunity
Compass Therapeutics is rated Buy, with risk/reward favoring upside after a sharp post-data selloff. CMPX's lead asset, tovecimig, showed strong PFS benefit in BTC, but OS crossover contamination clouds FDA approval prospects. The Q3 2026 FDA meeting is pivotal; approval could nearly double the stock, while rejection risks 50% dilution and multi-year delays.
Compass Minerals: Why This Turnaround Is Different
Compass Minerals (CMP) is undergoing a structural transformation, prioritizing disciplined capital allocation and operational efficiency over cyclical growth. CMP's portfolio simplification and focus on core salt and plant nutrition segments have improved cash flow, reduced debt, and strengthened financial stability. Despite a 14.9% EV/EBITDA discount to the sector median, CMP's ongoing deleveraging and operational gains are not yet recognized by the market.
Compass Minerals: Why I Think The Market Is Mispricing The Recovery
Compass Minerals International is rated Buy with a fair value range of $31–$36, reflecting 4–21% upside from current levels. Significant deleveraging, net leverage down from 4.6x to 2.7x, and S&P credit upgrade, positions CMP for multiple expansion. Salt cost normalization and Plant Nutrition margin gains are key forward catalysts; Salt's counter-cyclical cash flows enhance CMP's relative appeal.
Compass Pathways Eyes 2027 Launch as Psilocybin Depression Data Holds Up
Compass Pathways NASDAQ: CMPS said new 26-week data from its Phase 3 COMP006 trial further support the durability and safety profile of COMP360, its investigational psilocybin therapy for treatment-resistant depression, as the company works toward a potential U.S. launch in the first half of 2027.
